

Claire E Wainwright

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1623792/publications.pdf>

Version: 2024-02-01

176
papers

11,967
citations

36203

51
h-index

30010

103
g-index

182
all docs

182
docs citations

182
times ranked

9902
citing authors

#	ARTICLE	IF	CITATIONS
1	A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation. <i>New England Journal of Medicine</i> , 2011, 365, 1663-1672.	13.9	1,920
2	Lumacaftor+Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del <i>CFTR</i> . <i>New England Journal of Medicine</i> , 2015, 373, 220-231.	13.9	1,308
3	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. <i>Science</i> , 2016, 354, 751-757.	6.0	462
4	Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1219-1225.	2.5	449
5	Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic <i>Pseudomonas aeruginosa</i> Airway Infection. <i>Chest</i> , 2009, 135, 1610-1618.	0.4	353
6	Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. <i>Journal of Cystic Fibrosis</i> , 2004, 3, 67-91.	0.3	265
7	Genetic Modifiers of Liver Disease in Cystic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1076.	3.8	256
8	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del- <i>CFTR</i> : a randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 557-567.	5.2	243
9	A Multicenter, Randomized, Double-Blind, Controlled Trial of Nebulized Epinephrine in Infants with Acute Bronchiolitis. <i>New England Journal of Medicine</i> , 2003, 349, 27-35.	13.9	229
10	Ivacaftor treatment of cystic fibrosis in children aged 12 to \leq24 months and with a <i>CFTR</i> gating mutation (ARRIVAL): a phase 3 single-arm study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 545-553.	5.2	205
11	Lumacaftor+Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del <i>CFTR</i> . <i>New England Journal of Medicine</i> , 2015, 373, 1783-1784.	13.9	196
12	Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- <i>CFTR</i> mutation: a phase 3, open-label extension study (PERSIST). <i>Lancet Respiratory Medicine</i> , 2014, 2, 902-910.	5.2	191
13	Effect of Bronchoalveolar Lavage+Directed Therapy on <i>Pseudomonas aeruginosa</i> Infection and Structural Lung Injury in Children With Cystic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 163-71.	3.8	170
14	Series of laryngomalacia, tracheomalacia, and bronchomalacia disorders and their associations with other conditions in children. <i>Pediatric Pulmonology</i> , 2002, 34, 189-195.	1.0	154
15	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1522-1532.	2.5	146
16	Seasonal priority effects: implications for invasion and restoration in a semi-arid system. <i>Journal of Applied Ecology</i> , 2012, 49, 234-241.	1.9	141
17	Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. <i>Thorax</i> , 2004, 59, 149-155.	2.7	138
18	Nebulised hypertonic saline solution for acute bronchiolitis in infants. <i>The Cochrane Library</i> , 2013, , CD006458.	1.5	137

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 617-626.	5.2	129
20	Comparison of DNA Extraction Methods for Microbial Community Profiling with an Application to Pediatric Bronchoalveolar Lavage Samples. <i>PLoS ONE</i> , 2012, 7, e34605.	1.1	126
21	Cough-generated aerosols of <i>Pseudomonas aeruginosa</i> and other Gram-negative bacteria from patients with cystic fibrosis. <i>Thorax</i> , 2009, 64, 926-931.	2.7	122
22	Clonal strains of <i>Pseudomonas aeruginosa</i> in paediatric and adult cystic fibrosis units. <i>European Respiratory Journal</i> , 2004, 24, 101-106.	3.1	113
23	Nebulized hypertonic saline solution for acute bronchiolitis in infants. , 2008, , CD006458.		111
24	Early airway infection, inflammation, and lung function in cystic fibrosis. <i>Archives of Disease in Childhood</i> , 2002, 87, 306-311.	1.0	108
25	Rapid genotyping of <i>Pseudomonas aeruginosa</i> isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays. <i>Journal of Medical Microbiology</i> , 2004, 53, 1089-1096.	0.7	102
26	Acute viral bronchiolitis in children- a very common condition with few therapeutic options. <i>Paediatric Respiratory Reviews</i> , 2010, 11, 39-45.	1.2	102
27	Phenotypic Characterization of Clonal and Nonclonal <i>Pseudomonas aeruginosa</i> Strains Isolated from Lungs of Adults with Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1697-1704.	1.8	100
28	Exotic species display greater germination plasticity and higher germination rates than native species across multiple cues. <i>Biological Invasions</i> , 2013, 15, 2253-2264.	1.2	99
29	Identification of <i>Pseudomonas aeruginosa</i> by a duplex real-time polymerase chain reaction assay targeting the <i>ecfX</i> and the <i>gyrB</i> genes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 127-131.	0.8	90
30	Effect of Temperature on Cystic Fibrosis Lung Disease and Infections: A Replicated Cohort Study. <i>PLoS ONE</i> , 2011, 6, e27784.	1.1	87
31	Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and <i>P. aeruginosa</i> . <i>Journal of Cystic Fibrosis</i> , 2011, 10, 234-242.	0.3	86
32	Long term effects of denufosal tetrasodium in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 539-549.	0.3	85
33	Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. <i>Thorax</i> , 2013, 68, 643-651.	2.7	83
34	Evidence for Spread of a Clonal Strain of <i>Pseudomonas aeruginosa</i> among Cystic Fibrosis Clinics. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2266-2267.	1.8	81
35	Diagnosis of cystic fibrosis after newborn screening: The Australasian experience?twenty years and five million babies later: A consensus statement from the Australasian paediatric respiratory group. <i>Pediatric Pulmonology</i> , 2005, 39, 440-446.	1.0	79
36	Asthma and insulin resistance in children. <i>Respirology</i> , 2010, 15, 779-784.	1.3	79

#	ARTICLE	IF	CITATIONS
37	Viability of <i>Pseudomonas aeruginosa</i> in cough aerosols generated by persons with cystic fibrosis. <i>Thorax</i> , 2014, 69, 740-745.	2.7	79
38	A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. <i>Paediatric Respiratory Reviews</i> , 2016, 20, 55-66.	1.2	77
39	Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. <i>Thorax</i> , 2006, 61, 146-154.	2.7	75
40	Links between community ecology theory and ecological restoration are on the rise. <i>Journal of Applied Ecology</i> , 2018, 55, 570-581.	1.9	74
41	Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. <i>Pediatrics</i> , 2015, 136, 687-701.	1.0	72
42	Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 585-593.	2.5	67
43	Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 267-277.	5.2	66
44	Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. <i>Journal of Pediatrics</i> , 1996, 129, 367-373.	0.9	65
45	<i>Pseudomonas aeruginosa</i> genotypes acquired by children with cystic fibrosis by age 5-years. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 361-369.	0.3	61
46	Shared <i>Pseudomonas aeruginosa</i> genotypes are common in Australian cystic fibrosis centres. <i>European Respiratory Journal</i> , 2013, 41, 1091-1100.	3.1	59
47	A Clinical Pathway for Bronchiolitis is Effective in Reducing Readmission Rates. <i>Journal of Pediatrics</i> , 2005, 147, 622-626.	0.9	58
48	Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls. <i>Osteoporosis International</i> , 2003, 14, 404-411.	1.3	57
49	CFTR-dependent defect in alternatively-activated macrophages in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 475-482.	0.3	57
50	Nebulised hypertonic saline solution for acute bronchiolitis in infants. <i>The Cochrane Library</i> , 2017, 2017, CD006458.	1.5	57
51	Daily versus weekly azithromycin in cystic fibrosis patients. <i>European Respiratory Journal</i> , 2007, 30, 487-495.	3.1	55
52	Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1099-1114.	1.6	54
53	Disease surveillance using bronchoalveolar lavage. <i>Paediatric Respiratory Reviews</i> , 2008, 9, 151-159.	1.2	53
54	Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy. <i>Medical Journal of Australia</i> , 2008, 189, 578-582.	0.8	52

#	ARTICLE	IF	CITATIONS
55	Low Rates of <i>Pseudomonas aeruginosa</i> Misidentification in Isolates from Cystic Fibrosis Patients. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1503-1509.	1.8	52
56	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for <i>F508del</i> and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1361-1369.	2.5	50
57	Safety of bronchoalveolar lavage in young children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2008, 43, 965-972.	1.0	48
58	Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of <i>Pseudomonas aeruginosa</i> in People with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 348-355.	2.5	48
59	Climate moderates release from nutrient limitation in natural annual plant communities. <i>Global Ecology and Biogeography</i> , 2015, 24, 549-561.	2.7	47
60	Bacterial Causes of Empyema in Children, Australia, 2007-2009. <i>Emerging Infectious Diseases</i> , 2011, 17, 1839-1845.	2.0	46
61	Novel Neutrophil-Derived Proteins in Bronchoalveolar Lavage Fluid Indicate an Exaggerated Inflammatory Response in Pediatric Cystic Fibrosis Patients. <i>Clinical Chemistry</i> , 2007, 53, 1782-1791.	1.5	45
62	A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 438-450.	1.1	45
63	<i>Pseudomonas aeruginosa</i> antibiotic resistance in Australian cystic fibrosis centres. <i>Respirology</i> , 2016, 21, 329-337.	1.3	43
64	Distinct responses of niche and fitness differences to water availability underlie variable coexistence outcomes in semi-arid annual plant communities. <i>Journal of Ecology</i> , 2019, 107, 293-306.	1.9	40
65	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for <i>F508del</i> or heterozygous for the <i>F508del</i> -CFTR mutation and a residual function mutation. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 68-77.	0.3	37
66	Vitamin A levels in patients with CF are influenced by the inflammatory response. <i>Journal of Cystic Fibrosis</i> , 2004, 3, 143-149.	0.3	36
67	New treatments targeting the basic defects in cystic fibrosis. <i>Presse Medicale</i> , 2017, 46, e165-e175.	0.8	36
68	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the <i>G551D</i> -CFTR mutation treated with ivacaftor. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 83-88.	0.3	36
69	Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 94-101.	0.3	36
70	Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients. <i>PeerJ</i> , 2015, 3, e1223.	0.9	35
71	Value of serology in predicting <i>Pseudomonas aeruginosa</i> infection in young children with cystic fibrosis. <i>Thorax</i> , 2010, 65, 985-990.	2.7	34
72	The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 70-77.	0.3	34

#	ARTICLE	IF	CITATIONS
73	Face Masks Reduce the Release of <i>Pseudomonas aeruginosa</i> Cough Aerosols When Worn for Clinically Relevant Periods. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1339-1342.	2.5	34
74	Pubertal development and its influences on bone mineral density in Australian children and adolescents with cystic fibrosis. <i>Journal of Paediatrics and Child Health</i> , 2005, 41, 317-322.	0.4	33
75	Factors Influencing Acquisition of <i>Burkholderia cepacia</i> Complex Organisms in Patients with Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3975-3980.	1.8	33
76	Long-term safety and efficacy of tezacaftor/ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 733-746.	5.2	33
77	Quality-of-life in children and adolescents with cystic fibrosis managed in both regional outreach and cystic fibrosis center settings in Queensland. <i>Journal of Pediatrics</i> , 2006, 148, 508-516.e1.	0.9	32
78	<i>Aspergillus</i> and progression of lung disease in children with cystic fibrosis. <i>Thorax</i> , 2019, 74, 125-131.	2.7	32
79	Sources and dynamics of fluorescent particles in hospitals. <i>Indoor Air</i> , 2017, 27, 988-1000.	2.0	30
80	Protease IV production in <i>Pseudomonas aeruginosa</i> from the lungs of adults with cystic fibrosis. <i>Journal of Medical Microbiology</i> , 2006, 55, 1641-1644.	0.7	28
81	The social network of cystic fibrosis centre care and shared <i>Pseudomonas aeruginosa</i> strain infection: a cross-sectional analysis. <i>Lancet Respiratory Medicine</i> , 2015, 3, 640-650.	5.2	26
82	Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry. <i>Scientific Reports</i> , 2020, 10, 17421.	1.6	26
83	Particle and bioaerosol characteristics in a paediatric intensive care unit. <i>Environment International</i> , 2017, 107, 89-99.	4.8	25
84	Cyclic population dynamics and density-dependent intransitivity as pathways to coexistence between co-occurring annual plants. <i>Journal of Ecology</i> , 2018, 106, 838-851.	1.9	25
85	The Long Term Efficacy of Gastrostomy Feeding in Children with Cystic Fibrosis on Anthropometric Markers of Nutritional Status and Pulmonary Function. <i>Open Respiratory Medicine Journal</i> , 2009, 3, 112-115.	1.3	25
86	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. <i>Thorax</i> , 2021, 76, 1255-1265.	2.7	24
87	Clinical outcomes of Queensland children with cystic fibrosis: a comparison between tertiary centre and outreach services. <i>Medical Journal of Australia</i> , 2008, 188, 135-139.	0.8	23
88	Virulence factor expression patterns in <i>Pseudomonas aeruginosa</i> strains from infants with cystic fibrosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 1583-1592.	1.3	23
89	Cystic fibrosis pathogens survive for extended periods within cough-generated droplet nuclei. <i>Thorax</i> , 2019, 74, 87-90.	2.7	23
90	8. Asthma in children. <i>Medical Journal of Australia</i> , 1997, 167, 218-223.	0.8	22

#	ARTICLE	IF	CITATIONS
91	A Randomized Controlled Trial of an Interactive Voice Response Telephone System and Specialist Nurse Support for Childhood Asthma Management. <i>Journal of Asthma</i> , 2010, 47, 768-773.	0.9	22
92	Inhaled Corticosteroids and Respiratory Infections in Children With Asthma: A Meta-analysis. <i>Pediatrics</i> , 2017, 139, .	1.0	22
93	Expression of <i>Pseudomonas aeruginosa</i> Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
94	Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to <i>S. pneumoniae</i> infection due to oxidative damage and impaired innate immunity. <i>Scientific Reports</i> , 2019, 9, 2627.	1.6	21
95	Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 962-968.	0.3	21
96	Ivacaftor for patients with cystic fibrosis. <i>Expert Review of Respiratory Medicine</i> , 2014, 8, 533-538.	1.0	20
97	A comparison of two informative SNP-based strategies for typing <i>Pseudomonas aeruginosa</i> isolates from patients with cystic fibrosis. <i>BMC Infectious Diseases</i> , 2014, 14, 307.	1.3	20
98	A Novel Method and Its Application to Measuring Pathogen Decay in Bioaerosols from Patients with Respiratory Disease. <i>PLoS ONE</i> , 2016, 11, e0158763.	1.1	20
99	The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 669-678.	5.2	20
100	Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected <i>Pseudomonas aeruginosa</i> isolates from young children diagnosed with cystic fibrosis following newborn screening. <i>Clinical Microbiology and Infection</i> , 2013, 19, 266-272.	2.8	19
101	Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children. <i>Respirology</i> , 2012, 17, 114-119.	1.3	18
102	Loss of ATM in Airway Epithelial Cells Is Associated with Susceptibility to Oxidative Stress. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 391-393.	2.5	18
103	Fosfomycin - Investigation of a possible new route of administration of an old drug. <i>Journal of Cystic Fibrosis</i> , 2007, 6, 244-246.	0.3	17
104	Segniliparusrugosus Infection, Australia. <i>Emerging Infectious Diseases</i> , 2009, 15, 611-613.	2.0	17
105	Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia. <i>European Journal of Cancer Care</i> , 2014, 23, 721-727.	0.7	17
106	Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 428-434.	0.3	17
107	Genotypic Diversity within a Single <i>Pseudomonas aeruginosa</i> Strain Commonly Shared by Australian Patients with Cystic Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0144022.	1.1	17
108	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. <i>The Cochrane Library</i> , 2016, , CD009530.	1.5	17

#	ARTICLE	IF	CITATIONS
109	Differential expression of genes and receptors in monocytes from patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 342-348.	0.3	17
110	Costs of Bronchoalveolar Lavage-Directed Therapy in the First 5 Years of Life for Children with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2014, 165, 564-569.e5.	0.9	16
111	Effects of exotic annual grass litter and local environmental gradients on annual plant community structure. <i>Biological Invasions</i> , 2017, 19, 479-491.	1.2	16
112	Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 483-491.	0.3	16
113	Diagnosis and early life risk factors for bronchiectasis in cystic fibrosis: a review. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1003-1010.	1.0	15
114	<i>Pseudomonas aeruginosa</i> eradication therapy and risk of acquiring <i>Aspergillus</i> in young children with cystic fibrosis. <i>Thorax</i> , 2019, 74, 740-748.	2.7	15
115	Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 415-420.	0.3	15
116	Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 923-930.	0.3	15
117	A bedside assay to detect <i>Streptococcus pneumoniae</i> in children with empyema. <i>Pediatric Pulmonology</i> , 2011, 46, 179-183.	1.0	14
118	Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort. <i>European Respiratory Journal</i> , 2020, 55, 1901694.	3.1	14
119	The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 776-784.	5.2	14
120	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. , 2013, , CD009530.		13
121	Applied ecological research is on the rise but connectivity barriers persist between four major subfields. <i>Journal of Applied Ecology</i> , 2019, 56, 1492-1498.	1.9	13
122	Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. <i>Thorax</i> , 2021, 76, 487-493.	2.7	13
123	A Review of Telemedicine and Asthma. <i>Disease Management and Health Outcomes</i> , 2003, 11, 557-563.	0.3	12
124	Rapid single-nucleotide polymorphism-based identification of clonal <i>Pseudomonas aeruginosa</i> isolates from patients with cystic fibrosis by the use of real-time PCR and high-resolution melting curve analysis. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1403-1408.	2.8	12
125	Pneumonia in the first 2 years of life, and asthma in preschool-age children. <i>Pediatrics International</i> , 2011, 53, 576-580.	0.2	11
126	Multi-centre ethics and research governance review can impede non-interventional clinical research. <i>Internal Medicine Journal</i> , 2019, 49, 722-728.	0.5	11

#	ARTICLE	IF	CITATIONS
127	Total body water in children with cystic fibrosis using bioelectrical impedance. <i>Journal of Cystic Fibrosis</i> , 2004, 3, 243-247.	0.3	10
128	Misleading High Tobramycin Plasma Concentrations Can Be Caused by Skin Contamination of Fingerprick Blood Following Inhalation of Nebulized Tobramycin (TOBI?). <i>Therapeutic Drug Monitoring</i> , 2005, 27, 205-207.	1.0	10
129	Sensitivity of respiratory bacteria to lignocaine. <i>Pathology</i> , 2005, 37, 305-307.	0.3	10
130	The nutritional status of children with cystic fibrosis. <i>British Journal of Nutrition</i> , 2006, 95, 321-324.	1.2	10
131	Preserving Lung Function: The Holy Grail in Managing Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 833-835.	1.5	10
132	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 675-683.	0.3	10
133	The use of air displacement plethysmography in children and adolescents with cystic fibrosis. <i>European Journal of Clinical Nutrition</i> , 2004, 58, 985-989.	1.3	9
134	High-throughput single-nucleotide polymorphism-based typing of shared <i>Pseudomonas aeruginosa</i> strains in cystic fibrosis patients using the Sequenom iPLEX platform. <i>Journal of Medical Microbiology</i> , 2013, 62, 734-740.	0.7	9
135	Evaluating the impact of 2006 Australasian Clinical Practice Guidelines for nutrition in children with cystic fibrosis in Australia. <i>Respiratory Medicine</i> , 2018, 142, 7-14.	1.3	8
136	Emergence and impact of oprD mutations in <i>Pseudomonas aeruginosa</i> strains in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, e35-e43.	0.3	8
137	Targeted therapy for chronic respiratory disease: a new paradigm. <i>Medical Journal of Australia</i> , 2017, 206, 136-140.	0.8	7
138	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. <i>The Cochrane Library</i> , 2018, 9, CD009530.	1.5	7
139	Methods for tracking sagebrush-steppe community trajectories and quantifying resilience in relation to disturbance and restoration. <i>Restoration Ecology</i> , 2020, 28, 115-126.	1.4	7
140	Comparison of midline catheters and peripherally inserted central catheters to reduce the need for general anesthesia in children with respiratory disease: A feasibility randomized controlled trial. <i>Paediatric Anaesthesia</i> , 2021, 31, 985-995.	0.6	7
141	Pulmonary exacerbations as indicators of progression of lung disease in young children with CF. <i>Thorax</i> , 2013, 68, 608-609.	2.7	6
142	Oxygen saturation targets in infants with bronchiolitis. <i>Lancet, The</i> , 2015, 386, 1016-1018.	6.3	6
143	Response to: Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? by Jones and Barry. <i>Thorax</i> , 2016, 71, 185-186.	2.7	6
144	Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. <i>Gene</i> , 2019, 683, 12-17.	1.0	6

#	ARTICLE	IF	CITATIONS
145	Year in review 2010: Asthma, COPD, cystic fibrosis and airway biology. <i>Respirology</i> , 2011, 16, 540-552.	1.3	5
146	Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging. <i>Respirology</i> , 2014, 19, 448-460.	1.3	5
147	Current infection control practices used in Australian and New Zealand cystic fibrosis centers. <i>BMC Pulmonary Medicine</i> , 2020, 20, 16.	0.8	5
148	Characteristics of adverse medication events in a children's hospital. <i>Journal of Paediatrics and Child Health</i> , 2014, 50, 966-971.	0.4	4
149	Using the General Level Framework to guide training and development needs of pharmacists working in paediatrics. <i>Journal of Pharmacy Practice and Research</i> , 2015, 45, 322-330.	0.5	4
150	Asteraceae invaders have limited impacts on the pollination of common native annual species in SW Western Australia's open woodland wildflower communities. <i>Plant Ecology</i> , 2015, 216, 1103-1115.	0.7	4
151	Diverse outcomes of species interactions in an invaded annual plant community. <i>Journal of Plant Ecology</i> , 0, , rtw102.	1.2	4
152	Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease. <i>Respirology</i> , 2016, 21, 556-566.	1.3	4
153	Therapeutic targets and investigated treatments for Ataxia-Telangiectasia. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1263-1276.	0.5	4
154	Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 391-399.	0.3	4
155	Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 660-666.	1.1	4
156	Rapid macrolide and amikacin resistance testing for Mycobacterium abscessus in people with cystic fibrosis. <i>Journal of Medical Microbiology</i> , 2021, 70, .	0.7	4
157	Factors in childhood associated with lung function decline to adolescence in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 977-983.	0.3	4
158	Treatment of cystic fibrosis following infant screening. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 613-622.	0.2	3
159	What does advanced practice mean to Australian paediatric pharmacists? A focus group study. <i>International Journal of Pharmacy Practice</i> , 2015, 23, 141-149.	0.3	3
160	“Go for it, dream big, work hard and persist”: A message to the next generation of CF leaders in recognition of International Women's Day 2020. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 184-193.	0.3	3
161	Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration. <i>Paediatric Respiratory Reviews</i> , 2021, 37, 37-43.	1.2	3
162	High prevalence of a class 1 integron-associated aadB gene cassette in Pseudomonas aeruginosa isolates from an Australian cystic fibrosis patient population. <i>Pathology</i> , 2008, 40, 524-525.	0.3	2

#	ARTICLE	IF	CITATIONS
163	Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep. <i>Respirology</i> , 2017, 22, 1022-1034.	1.3	2
164	Looks can be deceiving: ecologically similar exotics have different impacts on a native competitor. <i>Oecologia</i> , 2019, 190, 927-940.	0.9	2
165	New therapies for people with CF in the CFTR modulator world. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 669-670.	0.3	2
166	Neutrophil respiratory burst activity is not exaggerated in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 707-712.	0.3	2
167	Treatment of Bronchiolitis. <i>New England Journal of Medicine</i> , 2003, 349, 1384-1385.	13.9	1
168	Electronic care records – Can they fulfil their promise?. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 608-609.	0.3	1
169	Alterations of the Nasopharyngeal Microbiota in Infants with Cystic Fibrosis. Cystic Fibrosis Transmembrane Conductance Regulator and Antibiotic Effects. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 473-474.	2.5	1
170	Cochrane review: Nebulized hypertonic saline solution for acute bronchiolitis in infants. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2010, 5, 1251-1273.	2.0	0
171	Seasonal priority effects: Implications for invasion and restoration in California coastal sage scrub. <i>Nature Precedings</i> , 2010, , .	0.1	0
172	Bronchoalveolar Lavage – Directed Therapy in Children With Cystic Fibrosis and <i>Pseudomonas aeruginosa</i> ; Infection – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1761.	3.8	0
173	Centralised versus outreach models of cystic fibrosis care should be tailored to the needs of the individual patient. <i>Internal Medicine Journal</i> , 2020, 50, 232-235.	0.5	0
174	Atypical haemolytic uraemic syndrome in a child with cystic fibrosis. <i>Journal of Paediatrics and Child Health</i> , 2021, , .	0.4	0
175	Cystic Fibrosis Cellular Treatments. , 2022, , 161-178.		0
176	Nontuberculous Mycobacterium. <i>Respiratory Medicine</i> , 2020, , 127-160.	0.1	0